Search | La Lingua Nostra

added article Health

2026-02-13 06:39:28 -

The "Bile Acid" Battle: How 2026 is Deciding the Fate of FXR Agonists.

By mid-2026, the industry has officially entered the era of "Targeted Recruitment." This year, the focus is on a critical re-evaluation of FXR agonists like cilofexor. Despite a disappointing Phase 3 result in late 2025 where it missed its primary fibrosis endpoint, researchers in 2026 are using AI-driven patient stratification to identify sub-groups—specifically those with early-stage...

0 Comments 0 Shares 14 Views 0 Reviews